

AUG 27 2004

PATENT  
DEAV1999/S001 US PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): BRANDENBURG ET AL. EXAMINER : MOHAMED, A.  
SERIAL NO. : 09/934,766 ART UNIT : 1653  
FILED : AUGUST 23, 2001  
FOR : COVALENTLY BRIDGED INSULIN DIMERS

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted  
via facsimile to the Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, at number 703-872-9306 on  
August 27, 2004.

Bonnie Stein  
(Print Full Name)

Bonnie Stein  
(Signature and Date) 8-27-04

AMENDMENT UNDER 37 C.F.R. 1.111

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Dear Sir:

In response to the outstanding office action dated June 16, 2004 and due for response on  
September 16, 2004, and in accordance with Rule 111 of the Rules of Practice, please amend the  
above-identified Application as follows.

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
**DEAV1999/S001US PCT**

Applicants:  
**Brandenburg, et al**

Serial No.  
**09/934,766**

Filing Date:  
**August 23, 2001**

Title of Invention:  
**Covalently Bridged Insulin Dimers**

**CERTIFICATE OF TRANSMISSION**  
I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at 703-872-9306, on  
Date of Deposit August 27, 2004  
Printed Name of Person Signing Certificate Bonnie Stein  
Signature Bonnie Stein

**Total Number of Pages Sent: 22**

**Attorney: William C. Coppola**

**Group Art Unit: 1653**  
**Examiner: Mohamed, A.**

TO: Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> Amendment, 37 CFR 1.111 (20 pgs.) | <input type="checkbox"/> Fee Transmittal                               |
| <input type="checkbox"/> Charge deposit account, in duplicate         | <input type="checkbox"/> Petition under 37 CFR _____                   |
| <input type="checkbox"/> Extension of Time Petition                   | <input checked="" type="checkbox"/> Other <u>Abstract Pg. - (1 pg)</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order        | <input type="checkbox"/> Other _____                                   |
| <input type="checkbox"/> Maintenance Fee Transmittal                  |  |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)